The experience of using ACE inhibitors and Ca channel blockers in the treatment of hypertension in patients with renal cell carcinoma
DOI:
https://doi.org/10.12775/JEHS.2022.12.02.027Keywords
renal cell carcinoma, hypertension, kidney cancerAbstract
Renal cell carcinoma (RCC) is one of widely spread urological cancers. It is known that approximately 26% of patients with a history of kidney cancer (KC) may have concomitant coronary artery disease, hypertension, diabetes mellitus and some other systemic diseases, which may lead to nephrosclerotic changes and the development or progression of the existing CRF.
The aim of the study. To study the renal function effects of ACE inhibitors (perindopril arginine) in patients with RCC, both as monotherapy and in combination with Ca channel blockers when conducting treatment of concomitant hypertension (HT).
Materials and methods. The study enrolled 38 patients with RCC. All patients were diagnosed with RCC for the first time, with their cancer staged according to the TNM International Classification (Т1 N0 M0).
Within a month, the use of combination therapy for kidney cancer complicated by Stage І, Degree ІІ hypertension was leading to increases in serum creatinine by 3 µmol/l and by 7 µmol/l in those patients where combination therapy was not used. In the meantime, during the same period, glomerular filtration rate reduced by 5 ml/min/1.73 m2 in patients of the first group and by 15 ml/min/1.73 m2 in patients of the second group.
References
Arakelian N.H., Shtryhol S.Yu. The effect of mexidol on antioxidant-prooxidant status in experimental acute renal failure. Current issues in design of new drugs: Proceedings of All-Ukrainian Applied Science Conference of Students and Young Scientists, 23-24 April 2009 [Article in Ukrainian]. Kharkiv: National University of Pharmacy, 2009. P. 205.
Hypotensive effect of urapidil: CNS site andrelative contribution / R. A. Gillis, K. L. Dretchen, I. Namath et al. J. Cardiovasc. Pharmacol. 2010. Vol. 9, No. 1. P. 103-109.
Votchal B.E. Essays on Clinical Pharmacology [in Russian]. Moscow: Medicine, 1965. – 414 pgs.
State Formulary of Medicinal Products: approved by the Order of the MOH of Ukraine dated 28.01.2010 No. 59 / Edited by V.T. Chumak, V.I. Maltsev, A.M. Morozov et al. Kyiv, 2010. Issue No. 2. 846 pgs.
Dudar I.O. Renoprotection: what a doctor can do today? [Article in Ukrainian] Ukrainian Medical Newspaper. 2006. No. 2. P. 6-10.
Dudar I.A. Herbal preparation Hofitol in the treatment of patients with kidney disease [Article in Russian]. Doctor. 2001. Vol. 10, No. 6. P. 54-56.
Effect of angiotensin II receptor blockade on renal disease progression in patients with nondiabetic chronic renal failure / J. Mora-Macia, A. Cases, K. Calero et al. Nephrol. Dial. Transplant. 2001. Vol. 16, suppl. 1. P. 82-84.
Hypotensive effect of urapidil: CNS site andrelative contribution / R. A. Gillis, K. L. Dretchen, I. Namath et al. J. Cardiovasc. Pharmacol. 2010. Vol. 9, No. 1. P. 103-109.
Relationship between hemoglobin level and quality of life in anemic patients with chronic kidney disease receiving epoetin alfa / P. Lefebvre, F. Vekeman, B. Sarokhan et al. Curr. Med. Res. Opin. 2006. Vol. 22, No. 10. Р. 1929-1937.
Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy / Sabatino M., Kim-Schulze S., Panelli M. C. et al. J. Clin. Oncol. 2009. Vol. 27, No. 16. Р. 2645-2652.
Skorupska E., Samborski W. Fizykoterapia w chorobach reumatycznych . Wielka Interna. Reumatologia / ed. Puszczewicz M. Warszawa: Medical Tribune, 2016. S. 515-522.
The health consequence of smoking: a report of the surgeon general / Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health. Washington, D. C., 2004. Р. 1-20.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Serhii Pasichnyk, Anatolii Gozhenko
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 332
Number of citations: 0